Another setback for Merck ( MRK ), although this one involved something of a long shot.

A Food and Drug Administration advisory panel Friday voted against the drugmaker's application to have the cholesterol drug Mevacor granted over-the-counter status.

It's the latest effort to have a prescription drug's status changed, or downgraded, to the more accessible OTC one.

Bristol-Myers Squibb ( BMY ) is seeking a similar change for its drug Pravachol.

In a related development, an FDA staff report Wednesday raised questions about how well consumers understand guidelines for Mevacor and how safely they would use it.

The agency usually goes along with the recommendations of its advisory committees.

A nonprescription version of Merck's drug Zocor has been available in the U.K. since July.

Merck shares rose 26 cents, or 0.8%, to $30.91.

More from Stocks

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Canopy Growth: First Cannabis Firm on the NYSE Fails to Generate Buzz

Canopy Growth: First Cannabis Firm on the NYSE Fails to Generate Buzz

Video: This Startup Connects Buyers and Sellers of Legal Marijuana

Video: This Startup Connects Buyers and Sellers of Legal Marijuana

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit